产时急性宫缩抑制对胎心率不可靠的疗效:能否降低剖宫产率?随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入4项随机对照试验共605例孕周>32周的单胎、产时胎心率不可靠患者,评估急性宫缩抑制对剖宫产率的影响。结果显示不同急性宫缩抑制药物间剖宫产率相似,与急诊分娩相比,β2受体激动剂可降低新生儿碱缺失>12 mmol/L的几率和新生儿重症监护病房入住率,并延长分娩时间间隔,但未降低剖宫产率,阿托西班和β2受体激动剂组剖宫产率反而升高。
要点
- 急性宫缩抑制未降低产时胎心率不可靠患者的剖宫产率。
- β2受体激动剂可降低新生儿碱缺失>12 mmol/L的几率(OR 0.61)和新生儿重症监护病房入住率(OR 0.42)。
- β2受体激动剂延长分娩时间间隔平均17.62分钟,但阿托西班和β2受体激动剂组剖宫产率升高。
核心结论
- 产时急性宫缩抑制用于胎心率不可靠时未降低剖宫产率。
- 急性宫缩抑制与短期胎儿结局改善相关,并安全地延长分娩时间间隔。
研究设计与样本
- 系统综述与随机对照试验的频率学派网络Meta分析,纳入4项随机对照试验共605例孕周>32周的单胎、产时胎心率不可靠患者。
- 检索MEDLINE/PubMed、Embase、Scopus、Cochrane对照试验中心注册库、ClinicalTrials.gov及国际临床试验注册平台,自各数据库建库至2022年2月。
- 采用意向性治疗原则,按原试验随机分组进行分析。
主要发现
- 不同急性宫缩抑制药物间剖宫产率相似。
- 与急诊分娩相比,β2受体激动剂降低新生儿碱缺失>12 mmol/L的几率(OR 0.61,95%CI 0.37-0.99)及新生儿重症监护病房入住率(OR 0.42,95%CI 0.22-0.78)。
- 与急诊分娩相比,β2受体激动剂延长分娩时间间隔(均数差17.62分钟,95%CI 15.66-19.58)。
- 剖宫产率未降低,阿托西班和β2受体激动剂组剖宫产率升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the effectiveness of intrapartum acute tocolysis for nonreassuring fetal heart rate tracing in decreasing the incidence of cesarean delivery. Secondary outcomes included modes of delivery other than cesarean delivery, successful acute tocolysis, time-to-delivery interval, and short-term perinatal outcomes. DATA SOURCES: Searches were performed in MEDLINE/PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and Reviews, ClinicalTrials.gov, and the International Clinical Trials Registry Platform from the inception of each database until February 2022. STUDY ELIGIBILITY CRITERIA: Selection criteria included randomized controlled trials of laboring patients with singleton gestations randomized to receive intrapartum acute tocolysis for nonreassuring fetal heart rate tracing, as defined by the original trial. METHODS: All analyses were done using an intention-to-treat approach, evaluating women according to the treatment group to which they were randomly allocated in the original trials. A frequentist network-meta-analysis was performed. RESULTS: Four randomized clinical trials were eligible, including 605 patients with nonreassuring fetal heart rate tracing and singleton gestations at gestational ages >32 weeks. The cesarean delivery rate was similar among patients managed with different types of acute tocolysis. Acute tocolysis, compared with emergency delivery, was associated with improved neonatal acid-base status (notably decreasing the prevalence of base deficit >12 mmol/L [beta-2 agonists odds ratio, 0.61; 95% confidence interval, 0.37-0.99] and the rate of neonatal intensive care unit admission [beta-2 agonists odds ratio, 0.42; 95% confidence interval, 0.22-0.78]) and with an increase in the time-to-delivery interval (beta-2 agonists mean difference, 17.62 minutes; 95% confidence interval, 15.66-19.58); there was no reduction of cesarean delivery rate, showing an increased rate with atosiban and beta-2 agonists. CONCLUSION: The cesarean delivery rate was not reduced by acute tocolysis when used for nonreassuring fetal heart rate tracing during labor. Acute tocolysis is associated with improved short-term fetal outcomes and safely increases the time-to-delivery interval.
引用
- Xodo S, de Heus R, Berghella V, et al. Acute tocolysis for intrapartum nonreassuring fetal status: how often does it prevent cesarean delivery? A systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2022. PMID: 35429665. doi:10.1016/j.ajogmf.2022.100639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。